Dr. Stacie L. Stapleton, M.D.
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
FL license ME98492
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $1,936 in total to this clinician.
| Day One Biopharmaceuticals | $1,830 |
|---|---|
| Catalyst Pharmaceuticals, Inc. | $106 |
| Consulting Fee | $1,830 |
|---|---|
| Food and Beverage | $106 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Day One Biopharmaceuticals Dec 11, 2025 | Consulting Fee OJEMDA · ONCOLOGY | $1,830 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $168,105 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Iovance Biotherapeutics, Inc. - DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Day One Biopharmaceuticals · Active, not recruiting · NCT05566795 - MEK-NF-201
Springworks Therapeutics, Inc. - Phase i ii open label study evaluating safety pharmacokinetics and efficacy of alectinib in pedia
Genentech, Inc. - LIGHTBEAM-U01 Substudy 01C# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.